MLL
CHRS icon

Moody Lynn & Lieberson’s Coherus Oncology CHRS Stock Holding History

Moody Lynn & Lieberson’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-11,040
Closed -$338K – 195
2015
Q1 		$338K Buy
+11,040
New +$285K 0.05% 141

Other funds holding CHRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Moody Lynn & Lieberson's CHRS Position: Q2 2015 in Review

Moody Lynn & Lieberson sold out of Coherus Oncology (CHRS) in Q2 2015, closing a stake of 11,040 shares — an estimated $338K sold.

Moody Lynn & Lieberson first reported a position in CHRS in Q1 2015 and held it in 1 quarter. The position peaked at $338K in Q1 2015. 75 funds tracked by Wall St. Rank hold CHRS as of Q2 2015.

  • Moody Lynn & Lieberson reported no remaining Coherus Oncology position as of Q2 2015 after selling out during the quarter.
  • Moody Lynn & Lieberson sold 11,040 Coherus Oncology shares in Q2 2015, an estimated $338K.
  • Moody Lynn & Lieberson first reported a position in Coherus Oncology in Q1 2015 and held it in 1 quarter.
  • Moody Lynn & Lieberson's Coherus Oncology position peaked at $338K in Q1 2015.
  • 75 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2015.

Based on Moody Lynn & Lieberson's 13F filing for Q2 2015, filed 25 Aug 2015.